A
part available to the medical corps in January 2007 ibandronate - Bonviva ® - differs from other osteoporosis drugs by taking monthly. An asset of course, to get a better adherence to osteoporosis treatments. A further step has been done with a form… quarterly and injection.Nearly 3 million of citizens suffer from osteoporosis. Women for the most part, with postmenopausal osteoporosis. They are just 600 000 to be diagnosed, whereas since 1 July 2006 examination that can detect the disease - osteodensitometrie - is covered by health insurance, for patients at risk of fractures.
Discutes under the french 20th Congress of Rheumatology in Paris, the results of ibandronate show a reduction in the osteoporosis risk of fractures and increased bone mineral density (BMD).
Interesting finally for patients who take oral is not possible, a quarterly injectable osteoporosis treatment is proposed since October. It is always the ibandronate issued by rapid intravenous ambulatory. It is a response to the sick who can not abide the constraints of oral intake.
The biphosphonates in fact must be taken on an empty stomach, and the patient must then keep a vertical position (seated or standing) for half an hour to an hour, without eating or drinking.
This alternative to the oral route is then likely to improve compliance among these patients. Note finally that these osteoporosis treatments require special precautions in case of oral health care.
